2024
Representation of female vascular surgeons in national clinical trial leadership: analysis of trends over 20 years
Kostiuk V, Thaxton C, Loh S, Cardella J, Dardik A, Tonnessen B. Representation of female vascular surgeons in national clinical trial leadership: analysis of trends over 20 years. JVS-Vascular Insights 2024, 2: 100077. DOI: 10.1016/j.jvsvi.2024.100077.Peer-Reviewed Original ResearchClinical trialsFemale vascular surgeonsVascular surgeonsMethods Clinical trialsArtery diseaseClinical trial leadershipSite principal investigatorsVascular conditionsAbdominal aortic aneurysmSurgeon-investigatorInvestigator-led trialsCarotid artery diseasePeripheral arterial diseaseCarotid diseaseProportion of womenVenous thrombectomyBoard certificationAortic aneurysmPercentage of womenIndustry-sponsored trialsTrial leadershipHemodialysis accessSubgroup analysisVascular surgerySurgeons
2004
Low-Molecular-Weight Heparin Versus Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients With Cancer
Tonnessen B, Money S. Low-Molecular-Weight Heparin Versus Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients With Cancer. Perspectives In Vascular Surgery And Endovascular Therapy 2004, 16: 144-146. DOI: 10.1177/153100350401600217.Peer-Reviewed Original ResearchWeight heparin groupRecurrent venous thromboembolismRecurrent thromboembolismVenous thromboembolismWeight heparinAnticoagulation groupHeparin groupOpen-label clinical trialLowmolecular-weight heparinAcute venous thromboembolismOral anticoagulant therapyDeep vein thrombosisGroup of patientsMolecular weight heparinLower mortality rateOral anticoagulantsAnticoagulant therapyPulmonary embolismVein thrombosisCancer patientsClinical trialsEffective therapyThromboembolismMortality ratePatients